4.6 Article

Cytomegalovirus Infection and the Risk of Mortality and Frailty in Older Women: A Prospective Observational Cohort Study

Journal

AMERICAN JOURNAL OF EPIDEMIOLOGY
Volume 171, Issue 10, Pages 1144-1152

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/aje/kwq062

Keywords

antibodies; viral; cytomegalovirus; frail elderly; immunoglobulin G; inflammation; interleukin-6; mortality; virus latency

Funding

  1. Atlantic Philanthropies
  2. American Geriatrics Society
  3. John A. Hartford Foundation
  4. Association of Subspecialty Professors
  5. National Institutes of Health [R01-AG027012, R01AG11703, R37-AG19905, P30-AG021334, N01AG12112]
  6. National Center for Research Resources [KL2-RR025006, UL1-RR025005]

Ask authors/readers for more resources

Cytomegalovirus (CMV), a prevalent pathogen, causes severe disease in immunocompromised humans. However, present understanding is limited regarding the long-term clinical effect of persistent CMV infection in immunocompetent adults. The authors conducted a prospective observational cohort study (1992-2002) of 635 community-dwelling women in Baltimore, Maryland, aged 70-79 years in the Women's Health and Aging Studies to examine the effect of CMV infection on the risk of frailty, a common geriatric syndrome, and mortality in older women. The effect of baseline serum CMV antibody (immunoglobulin G) concentration on the risk of 3-year incident frailty, defined by using a 5-component measure, and 5-year mortality was examined with Cox proportional hazards models. Compared with those who were CMV seronegative, women in the highest quartile of CMV antibody concentration had a greater incidence of frailty (hazard ratio = 3.46, 95% confidence interval: 1.45, 8.27) and mortality (hazard ratio = 3.81, 95% confidence interval: 1.64, 8.83). After adjustment for potential confounders, CMV antibody concentration in the highest quartile independently increased the risk of 5-year mortality (hazard ratio = 2.79, 95% confidence interval: 1.22, 6.40). Better understanding of the long-term clinical consequences of CMV infection in immunocompetent humans is needed to guide public health efforts for this widely prevalent infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available